Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program

Smac mimetics: implications for enhancement of targeted therapies in leukemia

(2010) E Weisberg et al.   LEUKEMIA

Molecular Characterization of the Pediatric Preclinical Testing Panel

(2008) G. Neale et al.   CLINICAL CANCER RESEARCH

c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor α (TNFα)-induced NF-κB Activation

(2008) Eugene Varfolomeev et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

cIAP1 and cIAP2 Facilitate Cancer Cell Survival by Functioning as E3 Ligases that Promote RIP1 Ubiquitination

(2008) Mathieu J.M. Bertrand et al.   MOLECULAR CELL

Initial testing of VNP40101M (Cloretazine®) by the pediatric preclinical testing program

(2008) Stephen T. Keir et al.   PEDIATRIC BLOOD & CANCER

Both cIAP1 and cIAP2 regulate TNF -mediated NF- B activation

(2008) D. J. Mahoney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program

(2007) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER